Q2 2026 Revenue Surges 20.1%, YTD Net Loss Narrows, Liquidity Strong Amidst Raised Guidance
CSTL sits 95% above its 52-week low of $14.59.
Summary
Castle Biosciences announced strong Q2 2026 revenue growth and improved year-to-date net loss, supported by a healthy liquidity position and raised full-year guidance.
Key Events · Earnings and Guidance · CSTL
-
Strong Q2 Revenue Growth
Net revenues for the second quarter of 2026 increased by 20.1% to $103.5 million compared to $86.2 million in Q2 2025, primarily driven by non-dermatologic tests.
-
Improved Year-to-Date Net Loss
The company's net loss for the six months ended June 30, 2026, improved by 22.2% to $(16.6) million, compared to $(21.3) million in the prior-year period.
-
Enhanced Year-to-Date Gross Margin
Year-to-date gross margin percentage significantly increased to 74.0% from 63.1% in the prior year, largely due to lower amortization expenses following the discontinuation of the IDgenetix test.
-
Solid Liquidity Position
As of June 30, 2026, the company held $266.8 million in total liquid assets (cash, cash equivalents, and marketable securities), which management expects to fund operations for at least the next 12 months.
Analysis · CSTL · Industrial Applications And Services
Castle Biosciences reported robust financial results for Q2 2026, with net revenues increasing by 20.1% year-over-year to $103.5 million, driven by strong growth in non-dermatologic tests. While the company recorded a net loss for the quarter, its year-to-date net loss significantly improved by 22.2% to $(16.6) million. The year-to-date gross margin also saw a substantial increase to 74.0%, primarily due to the discontinuation of the IDgenetix test. The company maintains a solid liquidity position with $266.8 million in cash and marketable securities, which it believes is sufficient for at least the next 12 months. This filing provides detailed financial confirmation of the positive Q2 performance and raised full-year guidance previously reported by Reuters.
At the time of this filing, CSTL was trading at $28.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $812.5M. The 52-week trading range was $14.59 to $44.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.